WHO Pharmaceuticals Newsletter 2005, No. 01
(2005; 12 pages) Ver el documento en el formato PDF
Índice de contenido
Cerrar esta carpetaREGULATORY MATTERS
Ver el documentoAMIODARONE - Medication Guide to be dispensed along with medicine
Ver el documentoATOMOXETINE - Labelling to include liver injury warning
Ver el documentoBENZATHINE BENZYL-PENICILLIN/PROCAINEBENZYLPENICILLIN - Label changes highlight appropriate use
Ver el documentoMEFLOQUINE - Patient Information Leaflet to help recognize adverse symptoms
Ver el documentoPARACETAMOL-DEXTROPROP-OXYPHENE - To be withdrawn due to risk of toxicity in overdose
Ver el documentoSMALLPOX VACCINE - Label to highlight reports of myopericarditis
Ver el documentoTHIORIDAZINE - Withdrawn due to poor benefit/risk profile
Abrir esta carpeta y ver su contenidoSAFETY OF MEDICINES
Abrir esta carpeta y ver su contenidoDRUGS OF CURRENT INTEREST
Abrir esta carpeta y ver su contenidoFEATURE
 

MEFLOQUINE - Patient Information Leaflet to help recognize adverse symptoms

Canada. Hoffman-La Roche is introducing an updated Patient Information Leaflet in every box of mefloquine (Lariam), used in the prophylactic treatment of malaria. The updated leaflet

• is intended to help patients recognize symptoms, including the sudden onset of unexplained anxiety, depression, restlessness, irritability, confusion, a persistently abnormal heartbeat, or palpitations, that may precede rare but potentially serious psychiatric, neurologic, or cardiac adverse events;

• advises patients who develop these symptoms to contact a health-care professional to assess the need for discontinuation of Lariam® (mefloquine) treatment and,

• includes a wallet card containing a summary of the most essential information, that may be cut out and carried by the patient during travel to areas with malaria.


Reference:

'Dear Health-care Professional' letter from Hoffman-La Roche, 24 January 2005. Available on the Internet at www.hc-sc.gc.ca

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 29 octubre 2018